Alnylam initiates phase 2 study of lumasiran in patients with recurrent kidney stone disease

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the company has initiated a global phase 2 study to evaluate the safety and efficacy of lumasiran, an rnai therapeutic targeting hydroxyacid oxidase 1 (hao1) – the gene encoding glycolate oxidase (go) – in patients with recurrent kidney stone disease and elevated urinary oxalate levels. lumasiran is approved by the u.s. food and drug administration (fda) f
ALNY Ratings Summary
ALNY Quant Ranking